Feed/Companies/Ambros Therapeutics

Ambros Therapeutics

As of 14 Oct 2026, Ambros Therapeutics has raised $125M across 1 verified round on record; latest: $125 million Series A led by Enavate Sciences and RA Capital Management, announced 16 Dec 2025.

BUILT ON

Visit site

Innovative medicines for diseases with high unmet medical need, specifically targeting Complex Regional Pain Syndrome Type 1.

ambrostherapeutics.comLinkedInIrvine, California

LATEST ROUND

Series A

$125M · 2025-12-16

RAISED ON RECORD · USD

$125M

across 1 verified round

INVESTORS

2 leads

SOURCES

from 1 publisher

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series A

$125M · 2025-12-16

[ HISTORY ]

led by Enavate Sciences, RA Capital Management

Round	Amount	Announced	Lead	Buzz
Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$125M	2025-12-16	Enavate Sciences, RA Capital Management	No recent discussion
1 source [ VERIFIED · CORRECTED ] read against 1 source Removed Patient Square Capital · no source places them in this round Lead added Enavate Sciences · prnewswire.com HQ added Irvine, California · prnewswire.com

Ambros Therapeutics

Company

Rounds

Sources

Profile

Investors

Ambros Therapeutics

Rounds

Profile

Sources

Series A$125M2025-12-161 source

Investors

Series A$125M2025-12-168 investors